Dysregulation of Ephx2 can contribute to carcinogenesis and more aggressive clinical phenotypes in the prostate, liver, and kidney (76, –78) and is highly expressed in prostate cancer (79). The gene discussed is EPHX2; the disease is prostate carcinoma.